AOB bald bei 3€ -- WKN 590111 - 500 Beiträge pro Seite

[Wachsam]

Gestern in USA ~ 20 % Plus, wenn das so weitergeht
dürfte die Aktie bald bei 3€ stehen.
Seit 3 Monaten im Höhenflug !

[Wachsam]

--------------------------------------------------------------------------------

American Oriental Bioengineering Reports Record First Quarter Results for 2005
American Oriental Bioengineering Reports Record First Quarter Results for 2005



BW5651 MAY 16,2005 6:06 PACIFIC 09:06 EASTERN



( BW)(AMERICA-ORIENTAL-BIO)(AOBO) American Oriental BioengineeringReports Record First Quarter Results for 2005

Business Editors

HONG KONG--(BUSINESS WIRE)--May 16, 2005--


Revenue Increases 63.3% Leading to a 91.1% Increase in Operating Income

America Oriental Bioengineering Inc., (OTCBB:AOBO), a rapidlygrowing Chinese company which produces and distributes a broad rangeof pharmaceutical and nutriceutical products, announced today recordfirst quarter results for the period ended March, 31, 2005. TheCompany reported revenue of $9.65 million, a 63.4% increase over firstquarter 2004 revenue of $5.91 million. American Oriental had operatingincome of $3.02 million, an increase of 91.1% over operating incomefor the 2004 first quarter of $1.58 million. American Orientalgenerated net income of $2.18 million in the current quarter, or $0.05per diluted share, an increase of 69.2% compared to $1.26 million, or$0.04 per diluted share for the same quarter last year.
The Company ended the quarter with $12.2 million in cash and cashequivalents, the strongest cash position in its history. AOBO´sshareholder´s equity increased to $35.3 million, its highest levelever.
AOBO´s first quarter results demonstrated that the acquisition ofHeilongjiang Songhuajiang Pharmaceutical Limited ("HSPL") hascontributed significantly to both revenue and earnings. Through thisacquisition, AOBO now offers a broader range of medicinal products inChina, such as Shuanghuanglian Lyophilized Powder Injection, which hasbeen in the market for over 15 years. The product is an importantantiviral medicine and has become one of the most highly regardedherbal products certified by the Government.
"We continue to rapidly grow our product lines and distributioncapabilities, both organically and through acquisition," said Tony(Shujun) Liu, Chairman and Chief Executive Officer of AmericanOriental Bioengineering, Inc. "Recently, we entered into a letter ofintent to acquire Heilongjiang Qitai Pharmaceutical Limited ("HQPL"),a leading Chinese distributor of pharmaceuticals. The transaction willprovide us, for the first time, with the ability to distribute ourproducts throughout China because of HQPL´s strong wholesale andretail distribution network, which should serve as a catalyst forfuture growth. We believe we are ideally positioned to continue torapidly increase revenue and earnings."

About American Oriental Bioengineering, Inc.

American Oriental Bioengineering, Inc. (AOBO) is a leading Chinesebiotechnology company that uses proprietary processes for producingsoybean protein peptide more efficiently than traditional extractingtechniques. These techniques are used to manufacture and formulatesupplemental and medicinal products. Soybean peptides are used widelyin general food, health food products and medicines, among otherapplications. AOBO also produces Cease-Enuresis Soft Gel, the onlyChinese FDA-approved first grade, prescription medicine that isspecially formulated to help alleviate bed-wetting and incontinence.The Company is a leading producer of products in both thenutriceuticals and pharmaceuticals areas in China. For moreinformation, visit http://www.bioaobo.com.

--30--AS/cg* CONTACT: CEOcast, Inc. for American Oriental Bioengineering, Inc. Ed Lewis, 212-732-4300 KEYWORD: MASSACHUSETTS HONG KONG INTERNATIONAL ASIA PACIFIC INDUSTRY KEYWORD: PHARMACEUTICAL BIOTECHNOLOGY EARNINGS SOURCE: America Oriental Bioengineering Inc.Copyright Business Wire 2005

(c) 2005 Business Wire. All reproduction, other than for an individual user`s reference, is prohibited without prior written permission.



Autor: © Business Wire , 15:06 16.05.05

[Wachsam]

Die Zahlen für das II. Quartal müssten auch
in Kürze erscheinen ?

[berndh70]

Aktuell in America wieder 0.05 USD im Plus.

Hat da eventuell jemand mehr Infos? Eventuell sind neue Zahlen im Umlauf?

[berndh70]

Aktie jetzt in USA auf 3,- USD!!

[berndh70]

AMERICAN ORIENTAL BIOENGINEERING REPORTS RECORD 2005 SECOND QUARTER RESULTS

Revenue Increases 98.2% and Income From Operations Increases 140.9% Leading to 122.5% Increase in Net Income; Company Reports Quarterly Diluted EPS of 8 Cents

America Oriental Bioengineering, Inc. (AMEX: AOB), a rapidly growing Chinese company that produces and distributes a broad range of pharmaceutical and nutraceutical products, announced today record second quarter and six-month results for the period ended June 30, 2004. The Company generated 2005 second quarter revenue of $11.9 million, a 98.2% increase compared to $6.0 million for the same period in 2004. American Oriental Bioengineering generated Income from Operations of $4.4 million, a 140.9% increase from $1.9 million in the 2004 second quarter. The Company had net income of $3.4 million, or $0.08 per basic and diluted share, a 122.6% increase versus $1.5 million, or $0.05 per basic and diluted share, for the comparable period in 2004.

For the six months ended June 30, 2005, American Oriental Bioengineering Inc. had revenue of $21.6 million, an increase of 81% compared to $11.9 million for the same six-month period in 2004. The Company reported Income from Operations of $7.5 million, a 117.8% increase from the $3.4 million reported for the same period in fiscal 2004. American Oriental Bioengineering generated net income of $5.5 million, or $0.14 per basic share ($0.13 per diluted share), a 100% increase compared to $2.8 million, or $0.08 per basic and diluted share for the first six months of fiscal 2004.

The Company ended the period with its strongest balance sheet ever, as it had cash and cash equivalents at June 30, 2005 of $14.9 million compared to $11 million at the end of the first six months of 2004.

Second quarter sales of the Company`s PBP Products (Plant Based Pharmaceutical Products) increased by 223% as compared to the same period in 2004, contributing to American Oriental Bioengineering`s strong results. This growth was primarily a result of an increase in sales of Cease Enuresis Soft Gel products. Also, the acquisition of HSPL (Heilongjiang Songhuajiang Pharmaceutical Ltd.) contributed to the increase in sales of PBP Products due to a broader product line. Sales of PBN Products (Plant Based Nutraceutical Products) increased by 21%, as a result of increased marketing and sales initiatives.

"We continue to experience rapid growth as a result of our innovative products and expanded distribution capabilities," said Tony (Shujun) Liu, Chairman and Chief Executive Officer of American Oriental Bioengineering, Inc. "The acquisition of HSPL has enabled us to expand our product line and enter new markets. Through the combination of new product initiatives and expanded sales and marketing activities and a strong balance sheet, we believe we are well positioned to continue to generate strong organic growth and to selectively pursue accretive acquisitions."

About American Oriental Bioengineering, Inc.

American Oriental Bioengineering, Inc. (AOBO) is a leading Chinese biotechnology company that uses proprietary processes for producing soybean protein peptide more efficiently than traditional extracting techniques. These techniques are used to manufacture and formulate supplemental and medicinal products. Soybean peptides are used widely in general food, health food products and medicines, among other applications. AOBO also produces Cease-Enuresis Soft Gel, the only Chinese FDA-approved first grade, prescription medicine that is specially formulated to help alleviate bed-wetting and incontinence. The Company is a leading producer of products in both the nutriceuticals and pharmaceuticals areas in China. For more information, visit http://www.bioaobo.com.

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks defined in this document and in statements filed from time to time with the Securities and Exchange Commission. All readers are encouraged to review the 8-K to be filed in connection with the acquisition discussed above, which outlines risk factors including debt obligations, deal terms and other relevant items. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the companies, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the companies disclaim any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

CONTACT: America Oriental Bioengineering, Inc.
Lily Li, 917-838-0689 (U.S.)
[phone] (China)
[e-mail]
or
Investors:
CEOcast, Inc. for American Oriental Bioengineering
Ed Lewis, 212-732-4300
[e-mail]

SOURCE: America Oriental Bioengineering, Inc.

[Bachalor]

ich poste mal 2 sachen
hatte ich als e-mails vor 6 wochen verschickt

nummer 1

AMERICAN ORIENTAL BIOENG - Nasdaq OTC BB: AOBO
>
>

Neue Tochtergesellschaft erzeugt $2.5 Million durch neue Aufträge -- Juni
27, 2005 --

American Oriental Bioengineering, Inc. (AOBO - Nachrichten), eine schnell
wachsende chinesische Firma, die eine breite Menge von pharmazeutischen
und nutraceutical Produkte produziert und verteilt, hat heute verkündet,
daß neue Marketing-Initiativen für Heilongjiang Songhuajiang
pharmazeutisches begrenztes (HSPL), eine vor kurzem erworbene
Tochtergesellschaft, $2.5 Million in den neuen Aufträgen erzeugt haben.
Für mehr als 50 Jahre hat HSPL eine führende Rolle in der chinesischen
pharmazeutischen Industrie gespielt. Sein Fokus auf R&D ergab eigene
Produkte wie Shuanghuanglian lyophilisierte Pulver-Einspritzung. Das
Produkt ist eine Antivirenmedizin und die in hohem Grade betrachteten
Kräuterprodukte, die durch die China FDA für die Behandlung von SARS
genehmigt werden. Die Firma hielt vor kurzem eine Reihe
Werbeveranstaltungen in acht Provinzen und Stadtbezirke in China ab,
einschließlich Heilongjiang, Hebei, Henan, Anhui, Xingjaing, Hunan,
Guangdong, Guangxi, Beijing, Tianjing ab. In diesen Treffen, bewirteten
AOBO`s technische Mitarbeiter, der Vertrieb und das Marketing Agenturen,
Verteiler und Kunden, um das Bewußtsein von Produkten HSPLs zu erhöhen.
Über 4.150 Verteilern wurden aufmnerksam. ", seit dem Erwerben von von
HSPL, haben wir einige bedeutende Initiativen genommen, um seine Einkommen
zu erweitern,", sagte Tony (Shujun) Liu, Generaldirektor AOBOs. "als
Privatunternehmen haben wir einige Absatzprogramme angefangen, um aus den
umfangreichen Investitionen Nutzen zu ziehen, die HSPL in der
Produktentwicklung gebildet hat. Wir haben auch unseren Kundenbestand
durch erweiterte Vertriebswege erhöht, wie durch die starke Anwesenheit
bei unseren kürzlich stattgefundenen Treffen demonstriert wurde. Wir
glauben, daß die einzigartige Produktserie HSPLs AOBO ein
Wettbewerbsvorteil im Markt bedeutet, und wir planen, auf vielen seiner
erfinderischen Produkte durch weitere Marketing-Tätigkeiten in der zweiten
Jahreshälfte Nutzen zu ziehen."






nummer 2


9.04.2005
American Oriental Bio. 100%-Chance
Global Biotech Investing

Die Experten von "Global Biotech Investing" sehen in der Aktie von
American Oriental Bioengeneering (ISIN US0287311072/ WKN 590111) eine
100%-Chance.

Das Unternehmen aus Hong Kong entwickle nahrungsergänzende Produkte und
pflanzliche Medikamente und verfüge über zwei Produktlinien mit über 100
Produkten. Für das abgelaufene Geschäftsjahr habe die Gesellschaft
Rekordergebnisse vorgelegt. So sei der Umsatz gg. VJ um mehr als 53% auf
32 Mio. USD und der Gewinn um knapp 70% auf 7,8 Mio. USD bzw. 0,20 USD je
Aktie gestiegen. Die liquiden Mittel seien von 5,4 auf 11,4 Mio. USD
gesteigert worden. Für das laufende Geschäftsjahr habe sich die
Geschäftsführung positiv geäußert.

Bei einem Börsenkurs um 1,50 USD sei der Titel an der Börse mit 60 Mio.
USD und einem KGV 2004 von 8 sehr günstig bewertet.

Sobald die Aktie von American Oriental Bioengeneering von Marktteilnehmern
entdeckt wird, ist der Titel mindestens für eine Kursverdopplung gut, so
die Experten von "Global Biotech Investing".

[berndh70]

heute mit 3.07 USD in America geschlossen...

[berndh70]

Kennt sich jemand mit Charttechnik aus, und kann mal einen Chart posten? Wo geht die Reise hin?

Danke schon mal im voraus...

[Wachsam]

Ich glaub wir 2 sind die einzigen, die sich für diese
Aktie interessieren.

Zumindestens habe wir hier keine Zocker an Board.

Charttechnik: Ich glaube bis 3€ geht es hoch,
dann kommt ein Rücksetzer bis 2,20 - 2,50 €

Möglich wäre ein Kurs von 5€, aber erst mal sehen
ob das mit den 3€ klappt ?

[Bienenvater]

Denke, das Teil schreit nach einer dringenden Konsolidierung.

[berndh70]

@wachsam

Ich denke, wenn das nur wir zwei sind, dann können wenigstens wir uns ordentlich freuen!

Heute waren wir ja schon mal an der 2,90 € Grenze. Bin gespannt wann die Kollegen in Amerika mit der Aktie heiß laufen. Letzte Woche gabs die bei uns teilweise noch für 1,85 €, wenn ich mich nicht irre!

Heute sind wir aktuell in USA schon wieder im plus, mal sehen, wo wir enden...

Ich wünsche ein schönes Wochenende!

[Bachalor]

[posting]17.617.750 von berndh70 am 19.08.05 16:56:11[/posting]es sind viel mehr
hatte diese aktie vor 6 wochen mit den verschiedenen kaufempfehlungen an gut 1200 user durch e-mail verteiler geschickt.
das war die neunte e-mail in gut 2 jahren,alle waren auf lange sicht gelaufen.
ist natürlich auch sehr viel glück dabei.
ich bitte meistens darum die leute in den threads weiterhin in ruhe ihr arbeit machen zu lassen.
den zocker und pusher sollte man damit nicht anziehen.

bienenvater hatte die mail z.b auch bekommen

[Braggo2]

Hallo Wachsam, hallo Berndh70,

gratuliere zur guten Performance, sehe auf dem aktuellen Niveau allerdings mehr Risiken als Chancen. Habe heute verkauft.
Am Wochenende erscheint im Darvas-Investor eine detaillierte Analyse zu dem Wert.
Probleme sind hier unter anderem die extrem schwankende Umsatzentwicklung einzelner Produkte und die starke Gewinnverwässerung durch die ständige Ausgabe von neuen Aktien.
Aus Bewertungssicht steht die Aktie mit einem geschätzten 05er-KGV von 15 bereits jetzt höher als ähnlich spekulative China-Aktien wie beispielsweise American Dairy (ADY) auch wenn der Vergleich auf Grund unterschiedlicher Branchenzugehörigkeit hinkt.

Deutlich aussichtsreicher ist hier ein anderer Chinawert, der um 1 Euro gehandelt wird, dessen Namen ich aber jetzt noch nicht verraten will, weil gerade noch dabei bin Positionen aufzubauen

[berndh70]

Hallo zusammen und Dank für Eure Postings.

Ich denke, ich werde sehen, ob sich zur 3,- € Marke noch etwas ergibt und die Position erst mal halten.

@braggo2: neugierig macht natürlich Dein Tipp, von dem wir vielleicht bald was hören werden?

In ein paar Minuten eröffnet USA, dann werden wir weiter sehen...

[Bachalor]

rt 3.72$

[Wachsam]

Na Bitte, wie ich es gesagt habe ?


3,-- €


Also jetzt würde ich sagen, geht es ermal auf
3,50 €

Dann sehen wir weiter ?

[Braggo2]

Tipp war CTRI, sorry hatte vergessen zu posten, heute ebenfals massiv im plus:


Viel besser gefällt mir stattdessen ein anderer China-Wert, der sich zwar innerhalb der letzten drei Wochen verdoppelt hat, aber trotzdem noch völlig unentdeckt ist. Es handelt sich um China Expert Technology (CTXI; WKN A0CACY), die in den USA nur OTC gehandelt werden. Darvasianer, die schon länger dabei sind, wissen, dass ich OTC-Werte im Normalfall strikt meide und auch hier werden wir von einer Depotaufnahme absehen, das gleich vorab.
Trotzdem scheinen in diesem Fall die Bewertungsrelationen und die Zukunftsperspektiven so aussichtsreich, dass ich Ihnen die Aktie nicht vorenthalten möchte.

CTXI mit Hauptsitz in Hongkong wurde 1998 gegründet und bietet IT-Netzwerk- und Infrastrukturservices verschiedenster Art (LAN, Softwareentwicklung, Webseiten-Gestalting, Hosting-Services etc.). Der Dreh an der Geschichte: Größter Kunde ist die chinesische Regierung. CTXI ist als einziges IT-Unternehmen in China autorisiert, die gesetzlich vorgeschriebene Überprüfung von großen IT-Projekten durchzuführen. Nach erfolgreich abgeschlossenen Modell-Projekten für den Aufbau großer Netzwerk-Infrastrukturen in der Provinz Fujjan sicherte man sich in den letzten Monaten zwei neue Großaufträge mit denen das Umsatzziel von 40 Millionen US-Dollar für das aktuelle Jahr gesichert sein sollte.

Der Hammer an der Geschichte: CTXI ist bereits hoch profitabel und erzielte in den letzten beiden Quartalen Gewinne von 0,105 US-Dollar im 2.Quartal bzw. 0,119 US-Dollar im 1.Quartal des aktuellen Geschäftsjahres. Verläuft das zweite Halbjahr ähnlich erfolgreich, und der positive Ausblich des Managements deutet darauf hin, dürften unter dem Strich 0,40 bis 0,45 US-Dollar in der Kasse hängen bleiben. Die Aktie notiert aktuell aber nur bei 1,31 US-Dollar. Das KGV läge damit – man traut es sich kaum zu schreiben – bei rund drei.
Die Umsätze in den ersten beiden Quartalen betrugen 8,6 bzw. 8,3 Millionen, die aktuelle Marktkapitalisierung des Unternehmens liegt bei 32 Millionen US-Dollar. Damit liegt das KUV bei sehr attraktiven 0,95.
Die Analysten von Spelman Research kommen zu einem entsprechend spektakulären Kursziel von 6,25 US-Dollar für die Aktie. Dies entspräche fast einer Verfünffachung vom aktuellen Kursniveau aus.
Trotzdem sollten Investoren sich des hohen Risikos bei einem Kauf bewusst sein: die geringe Größe des Unternehmens, die geringe Anzahl an Kunden und natürlich das signifikante Länderrisiko machen die Aktie nur für sehr risikobewusste Anleger zu einem Kauf. Käufe sollten unbedingt limitiert erfolgen, die Aktie grundsätzlich nur als spekulative Depotbeimischung gekauft werden.

Die Aktie wird unter relativ geringen Umsätzen auch in Deutschland unter der oben angegebenen WKN gehandelt. Auf dem aktuellen Niveau ist der Wert ein glasklarer Kauf!

[Wachsam]

In der Tat auf dem Weg nach 3,50 € !

[vergaser]

Einfach drinbleiben und Stop-Loss nachziehen.

[berndh70]

Also das mit den 3,- € ging ja schneller als erwartet. Glaube aber, dass wir langsam mit einer kleinen Konsolidierung rechnen müssen. Ich bin bei dem aktuellen Kurs ausgestiegen, die Versuchung war einfach zu groß ...

Allen weiter investierten viel Glück und gute Geschäfte...

[Wachsam]

So wie ich das sehe, wenn USA mitspielt, wird
die die 3,60 € Marke heute noch getestet ?

[vergaser]

Denkt ihr darüber nach zu verkaufen ?

Ich schätze die momentane Marktstimmung trotz des grossen Anstiegs der vergangenen Tage weiterhin bullish ein.

[Wachsam]

Also an aussteigen denke ich noch lange nicht !

[Wachsam]

Weiß Jemand ab wieviel Uhr an der Amex gehandelt wird ?

[Wachsam]

Wieso ist berndh70 eigentlich ausgestiegen ?

[berndh70]

@wachsam:

bin raus, da ich schon fast so lange dabei war wie Du, und nach einer fast Verdreifachung meines Kapitals war die Versuchung einfach zu groß. Ausserdem dachte ich an eine Konsolidierung nach diesem rasanten Kursverlauf.

Vielleicht gibt´s die Aktie in Kürze ja mal wieder günstiger ;-)

[Wachsam]

[berndh70]

Sieht ja weiter sehr gut aus mit der Aktie! Mal sehen, wann ich da wieder reinkomme.

Andere Frage an wachsam: Warum machst Du eigentlich 5 Threads zu der Aktie auf? Kennt sich doch langsam keiner mehr aus, oder?

[Wachsam]

[posting]17.682.331 von berndh70 am 25.08.05 14:10:28[/posting]Irgendwo haste recht. Ich weiß ja das die Aktie weiter steigen wird. Wenn sich hierfür sonst keiner interessiert
soll es mir jetzt auch egal sein.

[berndh70]

So, bin mit einer kleineren Position wieder dabei, allerdings glaube ich, dass man sich die nächsten Tage zu günstigen Kursen weiter eindecken kann. Aber die Aktie hat sicher weiteres Potential.

Anfang 2004 ist der Kurs mal bis 5.5 USD (=4.50€) gekommen, aber da waren die Voraussetzungen viel schlechter.

Die Firma hat dieses Jahr zwei super Quartale gehabt, die Produkte entwickeln sich gut und im Vertrieb hat man mit neuen Mitarbeitern und einem Firmenzukauf auch aufgestockt. Da kann man den Anstieg sicherlich eher auf gute Geschäfte denn auf vage Ankündigungen zurückführen.

Also wenn das den Kurs auf Sicht nicht weiter beflügelt...

[Wachsam]

[posting]17.688.016 von berndh70 am 25.08.05 21:26:47[/posting]Schön das Du wieder dabei bist !

[berndh70]

Jo, und in Amerika fast behauptet. Dachte, das geht noch ein wenig weiter runter. werde morgen sehen, was der deutsche Markt für Kurse hergibt. Eventuell geht sich ja ein Schnäppchen aus...

[berndh70]

So, und jetzt in die erwartete Konsolidierung.

Zeit, um sich weiter einzudecken....

[mlolo]

ich hau ma nen kauflimit bei 2€ rein. soweit dürfte es hoffentlich runtergehen

[berndh70]

Also ob sie auf 2,- € runtergeht, das wage ich zu bezweifeln. Aber schau ma mal, wie der Kaiser zu sagen pflegt. Aber auf diesem Kursniveau sicher auch schon ein Kauf. Werd mal sehen anfang der Woche weitere Positionen aufzubauen. Wenn das zweite Quartal schon so stark war, wie werden dann erst die letzten beiden? Und mit der amerikanischen Vertriebschefin werden die sicher versuchen auch in Amerika weiter voranzukommen. Da kommt also bestimmt noch was...

Hier eine kleine Aussicht:

Westminster Securities Initiates Equity Research Coverage of American Oriental Bioengineering, Inc. (Amex: AOB)

ATLANTA, July 18 /PRNewswire/ -- Westminster Securities Corporation has today initiated equity research coverage of Harbin, People`s Republic of China-based American Oriental Bioengineering, Inc. (Amex: AOB) with a "Strong Buy" investment rating, a six-month Target Price of $ 4.05, a 12-month Target Price of $ 4.50, and a risk rating of "High" over both time periods.

American Oriental Bioengineering is a manufacturer and distributor of herbal-based medicines, health supplements and soybean peptide products, all of which the company manufactures in China using organic raw materials. The company has been expanding its operations at a rapid pace over the past two years via selective acquisitions of other Chinese companies with complementary products or product distribution capabilities.

AOB is an investment banking client of Westminster Securities Corporation, which does not make a market in the trading of AOB shares.

[WissenMacht]

[Wachsam]

Na Bitte, läuft wie ein Uhrwerk !

[Trader03]

Wachsam du bist auch überall zu finden.

[Wachsam]

[posting]17.728.902 von Trader03 am 30.08.05 15:57:07[/posting]Überall nicht, aber überall wo es gut ist !

[WissenMacht]

nicht immer aber immer öfter

[berndh70]

Sieht aus, als ob wir heute in USA die 4,- USD Marke testen...

[Wachsam]

Ich stelle mich schon mal auf 4,-- € ein !

[mlolo]

kann mir mal jemand die aktuellen kennzahlen sagen? danke

[mlolo]

alles klar leute.hab den anderen thread gesehen

[berndh70]

4 Dollar - Punktlandung.

4,- € hört natürlich noch besser an!
ist man ja fast verleitet noch nachzulegen, aber stimmt, die starken Quartale kommen noch...

[teerecs]

meint ihr die korrigieren jetzt erst mal ein bisschen? hab gehofft die gehen noch weiter hoch

[berndh70]

Sollte Wachsam mit seinen 4,- € Kursziel doch schneller als erwartet richtig liegen? Aktuell in Amerika bei 4.41 USD und einem Handelsvolumen von über 2 Mio Stück.

Wenn das so weiter geht, dann geb ich dem Board bals ne Runde aus ;-))

[Wachsam]

Wenn heute USA nochmal mitspielt, gibt es die 4,00 Euro
diese Woche noch ?

Zugegeben,könnten auch 4,20 - 4,30 Euro werden.
Also weiter !!!!

[Glück]

[posting]17.618.464 von Bachalor am 19.08.05 17:49:32[/posting]Grüß Dich Bachalor,

Du hast im AOB Thread von einem Emailverteiler gesprochen.
Meintest Du den Darvas-Investor?

Gruss

Glück

[teerecs]

Ich habe mir die Zahlen auch nochmal genau angeguckt.

Nach Rücksprache mit meinem Informanten bin ich zum Ergebnis gekommen, dass AOB immer noch total unterbewertet ist.

Der faire Wert liegt bei mindestens 10 $, und wenn man das Wachstum mit einbezieht sogar höher.

Das schöne an der Aktie, die Fakten sind da!!!

[Wachsam]

[posting]17.813.362 von teerecs am 07.09.05 11:47:13[/posting]Du weißt garnicht wie Recht du hast. Ich selbst bin
durch meine Recherchen in den den letzten 10 Jahren zum
mehrfachen Millionär geworden.


Immer eín wenig Abwchslung im Depot. Aber am Ende im
einen Kunstgriff.

[teerecs]

hey da gratuliere ich dir ja!

das ist mir leider nicht gelungen, ich musste erstmal lehrgeld zahlen, weil ich keine ahnung von unternehmensbewertung hatte und immer mal kaufte was gerade cool war. neeee, sowas mach ich nicht mehr.

wenn man richtig recherchiert hat man viel mehr erfolg und man kann wirklich relativ sicher viel geld verdienen und ruhig schlafen. man weiß ja, das ding muss irgendwann steigen.

also bleibt schön wachsam!

[berndh70]

und wenn das so weiter geht, dann bin ich auch bald im Club!

USA heute: $ 5.15 +23.45%

Und das an einem Tag! Eigentlich dachte ich, bei 4.80-5.00 USD sei Schluß, aber die Aktie scheint ja gerade mal wieder in Fahrt zu kommen.

Wagt jemand der Beteiligten eine Prognose des weiteren Kursverlaufes abzugeben?

[Wachsam]

Kurzfristig vielleicht 4,50 €
Mittelfristig vielleicht 5,50 € (nächsten 3 Monate)
Langfristig (?)

[teerecs]

ich glaube sie wird nicht in dem tempo weitergehen, aber bis ende des jahres wird eine 6 vor dem komma stehen.

andere meinungen!?!?!?!?!?

[Wachsam]

[posting]17.876.570 von teerecs am 13.09.05 11:45:59[/posting]In 3 Monaten ist Jahresende.

[WissenMacht]

[vergaser]

Solider Anstieg, bei steigendem Volumen. Man scheint auch in Deutschland auf AOB aufmerksam zu werden.

[Wachsam]

Wie gesagt - kurzfristig 4,50 Euro

[Wachsam]

[posting]17.876.570 von teerecs am 13.09.05 11:45:59[/posting]Diese Aktie hat eben Dynamik

[vergaser]

Gewinne jetzt realisieren, weil es einen Rüchsetzer gab , hmmmmmmmmmmmm .


Eher Nein. Mal Abwarten.

Etwas mehr Zahlenmaterial wäre angemessen, findet Ihr nicht ?

[berndh70]

Werte Freunde der American Oriental Bioengineering,

ist ja die letzten Tage nicht so gut gelaufen, aber die Aktie hat sich sicher eine Erholung verdient. An den fundamental guten Daten ändert das nichts! Ich habe sogar nachgekauft und werde das bei diesen Kursen weiter machen.

Kennt sich jemand in Charttechnik aus? Wo sind da Widerstände etc..

Und dann brauchen wir nur wieder die Ergebnisse des letzten Quartals abwarten. Gute Company, gute Produkte, guter Markt

Ein entspanntes Wochenende allen Investierten!

[berndh70]

Hallo,

kleine Konsolidierung, und alle ziehen den Kopf ein?

Aktuell finde ich keine News, die einen triftigen Grund für die aktuelle Kursentwicklung gibt. Weiß jemand mehr? Ansonsten wohl eher eine Abkühlung, nachdem 3 Monate Steigflug angesagt waren. Ich bin noch wie vor der Meinung dabeibleiben lohnt sich!

[berndh70]

Kleine Meldung - große Wirkung:

HONG KONG--(BUSINESS WIRE)--Sept. 29, 2005--America Oriental Bioengineering, Inc. (AMEX: AOB), an emerging Chinese company that produces and distributes a broad range of pharmaceutical and nutraceutical products, announced today that it delivered a redemption notice with respect to all of its Class A warrants on September 6 and, as of September 26, all 7.5 million warrants have been exercised. Also, the Company delivered a redemption notice with respect to all of its Class B warrants on September 22, which would take effect on October 12, 2005. The warrants were issued in connection with the private placement that the Company completed on November 23, 2004. There are no other warrants currently outstanding other than Class A and Class B warrants described above.

Aber ich glaube, alle aus diesem Thread haben sich mittlerweile mit dem Gewinn zur Ruhe gesetzt, oder ...

[sirfrancisdrake]

und was heißt das für den Kurs ?Bitte um Antwort

[teerecs]

ich verstehe das so, dass beabsichtigt wird, herausgegebene anleihen vorzeitig zurückzuzahlen. das bedeutet in zukünftigen perioden mehr gewinn, da in zukunft keine rückzahlungen mehr erfolgen.

für diese periode entsteht jedoch eine mehrbelastung, da nun alle aufgenommenen kredite noch dieses jahr zurückgezahlt werden, was den gesamtgewinn und den gewinn pro aktie also für diese periode schmälert.

insgesamt betrachtet ist es aber langfristig besser, wenn schulden gleich zurückbezahlt werden.

jedenfalls hab ich die meldung so verstanden

für den kurs kann das auch was schlechtes heissen, kurzfristig. ansonsten ist die meldung natürlich super, da es zeigt wie finanzstark das unternehmen zur zeit ist und die gewinne wohl nur so sprudeln (auch wenn ein teil dieser gewinne halt erstmal für schuldentilgungen draufgeht).

[berndh70]

Hallo zusammen,

war ein paar Tage unterwegs.

Hier wieder aktuelle News. AOB hat seinen ersten Shop eröffnet und scheinbar wurden weitere Vertriebspartner gefunden. Das hört sich dch gut an.


HONG KONG--(BUSINESS WIRE)--Oct. 6, 2005--

``Life Peptide`` Opens in Times Square District of Hong Kong; Features AOB`s Soy Bean Peptide Products, Expands Distribution Channel

American Oriental Bioengineering, Inc. (AMEX: AOB), an emerging Chinese company that produces and distributes a broad range of pharmaceutical and nutraceutical products, announced that on August 12, the Company hosted a grand opening for its proprietary retail specialty store called "Life Peptide," located in the Times Square district of Hong Kong. "Life Peptide" will carry American Oriental Bioengineering soy bean peptide products, intending to respond to the growing demand for these products in new markets, such as Hong Kong. Soybean peptide products are sold over-the-counter remedies intending to promote general overall health for potential users and are utilized as a remedy for a variety of common ailments affecting a person`s overall health and wellbeing.

In addition to being sold at the "Life Peptide" store, the Company`s soy based peptide products will also be offered for sale by other nutraceutical chains commencing on October 15, 2005 including Manning China Resources and Health Plus. The Company expects its soy based peptide products to be on the shelves in approximately 100 stores from such chains.

"This opening of "Life Peptide" exemplifies our strategic business model of increasing the availability of our products to potential customers in under-penetrated and fast growing markets," commented Tony Liu, Chairman and CEO of American Oriental Bioengineering. "This initial move into the Hong Kong market with both our own store and through the distribution channel of other established retailers will increase our customer base with relatively low associated costs and also give us the opportunity to increase sales in the region on a faster basis. We look forward to growing our presence in the region as it becomes a significant contributor to our overall business."

[teerecs]

soja-peptide sind deshalb so gut, weil japaner, chinesen, thailänder und afrikaner milcheiweiss nicht vertragen.

wenn diese leute also zum beispiel aufbauprodukte für fitness benutzen wollen (und das wollen ja immer mehr, auch nur zur nahrungsergänzung), dann müssen sie auf sojapeptide zurückgreifen.

die sind auch so viel gesünder als proteine aus milcheiweiß!

der markt wird hier auf jedenfall beträchtliche zuwachsraten in den nächsten jahren haben.

[Wachsam]

Na die 6,00 € kommen schneller , als erwartet ?

[Wachsam]

Der Wahnsinn 6,00 € erreicht !!!!!!!!!!!!!!

[teerecs]

wir müssen den thread umbennenen:

AOB bald bei 30 Euro !!!

[berndh70]

Und am Montag gibt´s neue Zahlen! Ich glaube, da werden wir wieder schöne Neuigkeiten zu hören bekommen.

[Wachsam]

[posting]18.745.387 von berndh70 am 10.11.05 21:17:09[/posting]Die Vorboten haben den Kurs jedenfalls bestimmt. Übrigens
ich bin froh das Du wieder eingestiegen bist !

[teerecs]

aob ist ja einfach nur geil!

heute früh korrigieren sie um 10% und ich denke mir noch, es wurde auch mal zeit für ne kurze korrektur... ABER NEIN! schon sind sie wieder kurz vorm plus und streben nach neuen höhen!

JIPPIEEEE!

[Wachsam]

Ich hoffe für den Kursrutsch gibt es eine Erklärung ?
Will mich mal bis 5,00 USD gedulden. Unter 5,00 USD
bin ich erst mal raus !

[Wachsam]

AOB > SEC Filings for AOB > Form 10QSB on 14-Nov-2005 All Recent SEC Filings




Show all filings for AMERICAN ORIENTAL BIOENGINEERING INC | Request a Trial to NEW EDGAR Online Pro

Form 10QSB for AMERICAN ORIENTAL BIOENGINEERING INC


--------------------------------------------------------------------------------

14-Nov-2005

Quarterly Report



ITEM 2. MANAGEMENT`S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following discussion should be read in conjunction with the information contained in the condensed consolidated financial statements of the Company and the notes thereto appearing elsewhere herein and in conjunction with the Management`s Discussion and Analysis set forth in (1) the Company`s Annual Report on Form 10-KSB for the year ended December 31, 2004, as amended (which is also incorporated by reference herein) and (2) Quarterly Report on Form 10-QSB for the quarter ended September 30, 2004.

As used in this report, the terms "Company", "we", "our", "us" and "AOB" refer to American Oriental Bioengineering, Inc., a Nevada corporation.

PRELIMINARY NOTE REGARDING FORWARD-LOOKING STATEMENTS



This quarterly report contains forward-looking statements within the meaning of the federal securities laws. These include statements about our expectations, beliefs, intentions or strategies for the future, which we indicate by words or phrases such as "anticipate," "expect," "intend," "plan," "will," "we believe," "AOB believes," "management believes" and similar languages. The forward-looking statements are based on the current expectations of AOB and are subject to certain risks, uncertainties and assumptions, including those set forth in the discussion under "Management`s Discussion and Analysis of Financial Condition and Results of Operations" on this report. The actual results may differ materially from results anticipated in these forward-looking statements. We base the forward-looking statements on information currently available to us, and we assume no obligation to update them.

Investors are also advised to refer to the information in our filings with the Securities and Exchange Commission, especially on Forms 10-KSB, 10-QSB and 8-K, in which we discuss in more detail various important factors that could cause actual results to differ from expected or historic results. It is not possible to foresee or identify all such factors. As such, investors should not consider any list of such factors to be an exhaustive statement of all risks and uncertainties or potentially inaccurate assumptions.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES



We have identified one policy area as critical to the understanding of our consolidated financial statements. The preparation of our consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of sales and expenses during the reporting periods. With respect to net realizable value of the Company`s accounts receivable and inventories, significant estimation judgments are made and actual results could differ materially from these estimates.

The Company had not provided any reserves against its accounts receivable at December 31, 2004. In 2005, the management of the Company provided reserves on its accounts receivable to reflect management`s expectation on the collectibility of aged accounts receivable. Management`s estimation of the reserves on accounts receivable at September 30, 2005 was based on the current facts that there is significant aged accounts receivable. In making their judgment, management has assessed customers` ability to continue to pay their outstanding invoices timely, and whether their financial position will deteriorate significantly in the future, which would result in their inability to pay their debts to the Company. As at September 30, 2005, the Company provided $307,106 reserves for accounts receivable.

The Company had not provided any reserves against its inventories at December 31, 2004. At September 30, 2005, the Company provided $606,927 against its inventories, of which $131,551 was provided against the inventories of Three Happiness and $475,376 was provided against the inventories of HSPL. Management`s estimation that a provision is needed is based on the current facts that there are potential impairments on the current carrying value of the inventories due to potential obsolescence as a result of aged inventories. The Company might not be able to realize the existing carrying value of the inventories. In making their judgment, management made their estimations on the potential impairments based on the demand for their products in the future and the trends of turnover of the inventories.

While the Company`s management currently believes that there is little likelihood that the actual results of their current estimates will differ materially from such current estimates, if customer demand for its products decreases significantly in the near future, or if the financial position of its customers deteriorates in the near future, the Company could realize significant write downs for slow moving inventories or uncollectible accounts receivable.

We believe the following is among the most critical accounting policies that impact our consolidated financial statements. We suggest that our significant accounting policies, as described in our consolidated financial statements in the Summary of Significant Accounting Policies, be read in conjunction with this Management`s Discussion and Analysis of Financial Condition and Results of Operations.

We recognize revenue in accordance with Staff Accounting Bulletin ("SAB") No.
104. All of the following criteria must exist in order for us to recognize revenue:

1. Persuasive evidence of an arrangement exists;
2. Delivery has occurred or services have been rendered;
3. The seller`s price to the buyer is fixed or determinable; and
4. Collectibility is reasonably assured.

The majority of the Company`s revenue results from sales contracts with distributors and revenues are generated upon the shipment of goods. The Company`s pricing structure is fixed and there are no rebate or discount programs. Management conducts credit background checks for new customers as a means to reduce the subjectivity of assuring collectibility. Based on these factors, the Company believes that it can apply the provisions of SAB 104 with minimal subjectivity.

RESULTS OF OPERATIONS - THREE MONTHS ENDED SEPTEMBER 30, 2005 AS COMPARED TO
THREE MONTHS ENDED SEPTEMBER 30, 2004




Revenues, Cost of Revenues and Gross Margin
-------------------------------------------

Revenues for the quarter ended September 30, 2005 were $13,407,237, an increase
of $6,034,682 from $7,372,555 for the quarter ended September 30, 2004. Compared
to the same quarter in 2004, our sales revenues from our two main categories of
products in the current quarter of 2005 were as follows:


Three Months Ended September 30,
---------------------------------------------- Increase /
Product 2005 2004 (Decrease)
--------------------------------------------- --------------------- -------------------- ---------------
Plant based pharmaceuticals products (PBP
Products) $ 8,626,712 $ 3,150,091 $ 5,476,621
Plant based nutraceuticals products (PBN
Products) 4,780,525 4,222,464 558,061

--------------------- -------------------- ---------------
TOTAL $ 13,407,237 $ 7,372,555 $ 6,034,682
===================== ==================== ===============

In the third quarter of 2005, the sales of our PBP Products increased by
$5,476,621 or 174% as compared to the same period in 2004. This was mainly due
to the increase in Cease Enuresis Soft Gel sales. Also, the acquisition of HSPL,
completed on November 22, 2004 contributed to an increase in sales of PBP
Products because HSPL produces and sells various types of PBP Products to the
market and through the acquisition of HSPL, AOB enriched its product mix on PBP
Products.

The sales revenue from our PBN Products increased to $4,780,525 in the third
quarter of 2005 from $4,222,464 from the same period in 2004, representing an
increase of 13%. In the third quarter of 2005, our marketing and promotion
efforts continued to help us to increase our sales in PBN Products.

Cost of revenues for the quarter ended September 30, 2005 were $4,911,990, an
increase of $2,475,833 from $2,436,157 for the same quarter last year. The
increases in costs of sales by product categories were as follows:

Three Months Ended September 30,
---------------------------------------------- Increase /
Product 2005 2004 (Decrease)
--------------------------------------------- --------------------- -------------------- ---------------

PBP Products $ 3,198,873 $ 993,441 $ 2,205,432
PBN Products 1,713,117 1,442,716 270,401

--------------------- -------------------- ---------------
TOTAL $ 4,911,990 $ 2,436,157 $ 2,475,833
===================== ==================== ===============




The cost of sales of our PBP Products increased by $2,205,432, or 222% in third quarter of 2005 compared to same period in 2004. This increase resulted from our 174% increase in sales revenue from our PBP Products sold through Harbin Bioengineering in the same period as compared to last year and our sales of additional PBP Products resulting from our acquisition of HSPL completed on November 22, 2004. The cost of sales increased in higher proportion than our increase in revenue because the gross profit margin of HSPL was lower than that of Harbin Bioengineering and in the same quarter of 2004 the revenue and cost of sales of HSPL had not been consolidated into AOB.

The cost of sales of our PBN Products increased by $270,401, or 19% in the third quarter of 2005 compared to the same period in 2004. This increase resulted from our 13% increase in sales revenue from PBN Products during the third quarter of 2005 as compared to same period in 2004. The percentage increase in cost of sales was slightly higher than the percentage increase in sales revenue because of normal fluctuations in production overhead and spoilage during the production process.

Compared to the third quarter of 2004, the percentage profit margin for our Company decreased from 67% to 63% in the current quarter. The decrease in the percentage profit margin was mainly attributable to the average percentage profit margin of HSPL, which was lower than the average percentage profit margin of all products of Harbin Bioengineering. The profit margin for PBP Products decreased from 68% in the same quarter last year to 63% in current quarter. The decrease was due to the profit margin of PBP Products from HSPL, which was lower than the average profit margin of PBP Products from Three Happiness while in the same quarter last year the financial results of HSPL was not incorporated in AOB. For PBN Products, the profit margin decreased from 66% in the same quarter last year to 64% in current quarter. The decrease was due to normal fluctuations in production overhead and spoilage during the production process.


Selling and Marketing

Selling and marketing expenses amounted to $850,167 in the third quarter of
2005, an increase of $341,690 as compared to the same period in 2004 of
$508,477. The breakdown of the expenses were as follows:

Three Months Ended September 30,
-------------------------------------------------
2005 2004
----------------------- ---------------------
Payroll expenses for Harbin Bioengineering $ 160,648 $ 138,531
Non payroll expenses for Harbin Bioengineering 285,686 369,382
Payroll expenses for HSPL 44,060 0
Non payroll expenses HSPL 352,970 0
Overhead for offices in Hong Kong and the United States 6,803 564

----------------------- ---------------------
TOTAL $ 850,167 $ 508,477
======================= =====================




In the third quarter of 2005, the Company incurred $160,648 for the payroll of our sales and marketing executives and employees in Harbin Bioengineering, or an increase of 16% from $138,531 in the same quarter in 2004. This increase was mainly due to an increase in the number of employees in our sales and marketing department. In the third quarter of 2005, HSPL incurred $44,060 in payroll

expenses for sales and marketing executives and employees and $352,970 in overhead expenses. In the same quarter last year there was no such expense because operating results of HSPL was not yet consolidated with the Company. AOB also incurred $6,803 for sales and marketing activities in our Hong Kong and US offices, an increase of $6,239 from the same quarter last year.

Advertising



Advertising expenses for the quarter ended September 30, 2005 amounted to $756,541, an increase of 4% as compared with $728,802 in the same quarter in 2004. The Company spent roughly the same expenses in advertising in the current quarter compared to the same quarter last year.


General and Administrative
--------------------------

General and administrative expenses increased from $892,701 in the third quarter
of 2004 to $1,939,514 in the same quarter this year, or a 117% increase.
Compared to the same quarter in 2004, our increase in the expenses was due to
the following:


Three Months Ended
September 30,
------------------------------------------ Increase /
Breakdown of expenses: 2005 2004 (Decrease)
-------------------------------------------------- ------------------- ------------------ ---------------
Harbin Bioengineering - payroll $ 121,266 $ 89,932 $ 31,334
Harbin Bioengineering - non payroll 387,123 304,712 82,411
HSPL - payroll 26,844 - - 26,844
HSPL - non payroll 283,166 - - 283,166
AOB Hong Kong office overhead 115,272 44,974 70,298
AOB US office overhead 77,257 - - 77,257
Professional fees 595,128 - - 595,128
Stock based consultant expenses 209,708 361,333 (151,625)
Executive compensation 91,750 91,750 - -
ESOP expense 32,000 - - 32,000

------------------- ------------------ ---------------
TOTAL $ 1,939,514 $ 892,701 $ 1,046,813
=================== ================== ===============




During the third quarter of 2005, the Company incurred $121,266 in payroll expenses for Harbin Bioengineering as compared to $89,932 in 2004. This increase resulted from an increase in the total number of employees. The non payroll expenses of Harbin Bioengineering increased by $82,411. This was mainly due to $131,551 reserves against inventories in the third quarter of 2005 that was not happened in the same quarter last year, offset by reduction in general overhead of $49,140 as a result of shift of portion of administrative activities to Hong Kong and US offices.

During the third quarter of 2005, HSPL incurred $26,844 and $283,166 of payroll and non payroll expenses, respectively. There were no similar expenditures in the same quarter of 2004 because the operation of HSPL was not consolidated with AOB in the same quarter last year.

The Company incurred $115,272 and $77,257 in overhead expenses for Hong Kong and US offices, respectively. In the same period last year the Company incurred a total of $44,974 to maintain the Hong Kong offices. The increase was due to increase in administrative activities in Hong Kong office and in the same quarter last year the US office was not established.

In the current quarter of 2005, the Company incurred professional expenses of $595,128 for professional expenses related to $6 million investments and related warrants administrations that did not occur in the same quarter last year.

The Company spent $32,000 in ESOP expenses in the current quarter and there was no ESOP expenses incurred in the same quarter last year. In the same quarter last year the Company did not issue any employee stock options to any of the directors.

Depreciation and Amortization



Depreciation and amortization of plant and equipment increased $164,648 in the third quarter of 2005 compared to the same period in 2004. The increase was mainly due to an increase in assets as a result of the HSPL acquisition.

Income Taxes



Income tax expense was $1,126,721 for the quarter ended September 30, 2005, as compared to $444,361 for the quarter ended September 30, 2004. The increase was due to the increase in income before income taxes of Harbin Bioengineering and the contribution of profit from HSPL, which could not be offset against the losses of AOB.

The income tax was provided at 15% of income before tax at the Harbin Bioengineering level and 33% at the HSPL level in China. The effective tax rate applied for tax expense in the current quarter, however, was 23% instead of 17% in 2004 (weighted average of the tax rate for Harbin Bioengineering and HSPL). This was because there were other operating expenses incurred at the holding company level as well as AOB HK and AOB US, and these expenses could not enjoy tax benefits in China and so the effective income tax rate provided for the Company was 23%.

Net Income



In the third quarter of 2005, our net income increased by $1,468,719 to a net income of $3,709,764 from a net income of $2,241,045 in the same quarter in 2004.

Foreign Currency Translation Gain



In the third quarter of 2005, we recognized foreign currency translation gain of $854,058 as a result of appreciation of Renminbi against US Dollar during July 2005. There was no such appreciation in the same quarter last year.


RESULTS OF OPERATIONS - NINE MONTHS ENDED SEPTEMBER 30, 2005 AS COMPARED TO NINE
--------------------------------------------------------------------------------
MONTHS ENDED SEPTEMBER 30, 2004
-------------------------------

Revenues, Cost of Revenues and Gross Margin
-------------------------------------------

Revenues for nine months ended September 30, 2005 were $34,962,489, an increase
of $15,679,355 from $19,283,134 for nine months ended September 30, 2004.
Compared to same period in 2004, our sales revenues from our two main categories
of products in the nine months ended 2005 were as follows:



Nine Months Ended September 30,
---------------------------------------------- Increase /
Product 2005 2004 (Decrease)
----------------------------------------- --------------------- ------------------- ----------------
PBP Products $ 22,052,419 $ 10,403,812 $ 11,648,607
PBN Products 12,910,070 8,879,322 4,030,748

--------------------- ------------------- ----------------
TOTAL $ 34,962,489 $ 19,283,134 $ 15,679,355
===================== =================== ================

In the first nine months of 2005, the sales of PBP Products increased by
$11,648,607 or 112% as compared to the same period in 2004. This was mainly due
to the increase in Cease Enuresis Soft Gel sales by Harbin Bioengineering and
also to the increase in sales of PBP Products subsequent to the acquisition of
HSPL. HSPL contributed to an increase in sales of PBP Products because HSPL
produces and sells various types of PBP Products to the market and through
acquisition of HSPL, AOB enriched its product mix on PBP Products.

The sales revenue from our PBN Products increased to $12,910,070 in the first
nine months of 2005 from $8,879,322 from the same period in 2004, representing
an increase of 45%. In first nine months of 2005 our marketing and promotion
efforts continued to help us to increase our sales in health food supplements,
which resulted in an increase in sales.

Cost of revenues for the first nine months ended September 30, 2005 were
$12,728,309, an increase of $6,629,566 from $6,098,743 for the same period last
year. The increases in costs of sales by product categories were as follows:

Nine Months Ended September 30,
---------------------------------------------- Increase /
Product 2005 2004 (Decrease)
----------------------------------------- --------------------- ------------------- ----------------

PBP Products $ 8,184,755 $ 3,168,688 $ 5,016,067
PBN Products 4,543,554 2,930,055 1,613,499

--------------------- ------------------- ----------------
TOTAL $ 12,728,309 $ 6,098,743 $ 6,629,566
===================== =================== ================




The cost of sales of our PBP Products increased by $5,016,067, or 158% in first nine months of 2005 compared to the same period in 2004. The increase resulted from our 112% increase in sales revenue from our PBP Products sold through Harbin Bioengineering in the same period as compared to last year and the increase in sales of PBP Products through HSPL subsequent to the acquisition.

The cost of sales of our PBN Products increased by $1,613,499, or 55% in the first nine months of 2005 compared to the same period in 2004. This increase resulted from our 45% increase in sales revenue from our PBN Products during the first nine months of 2005 as compared to same period in 2004. The percentage increase in cost of sales was higher than the percentage increase in sales revenue as in the same period of 2004 because the Company recorded exceptional higher profit margin of PBN products in the same period last year that did not repeated this year.

Compared to the first nine months of 2004, the percentage profit margin for our Company decreased from 68% to 64% in the same period of 2005. The decrease in percentage profit margin was mainly attributable to the percentage profit margin of HSPL was lower than the average percentage profit margin of all products of Harbin Bioengineering. The profit margin for PBP Products decreased from 70% in the period ended September 30 last year to 63% in same period in the current year. The decrease was due to the profit margin of PBP Products from HSPL was lower than the average profit margin of PBP Products from Three Happiness while in the same period last year the financial results of HSPL was not incorporated in AOB. For PBN Products, the profit margin decreased from 67% in the first nine month last year to 65% in same period in the current year. The decrease was due to normal fluctuations in production overhead and spoilage during the production process.


Selling and Marketing
---------------------

Selling and marketing expenses increased from $1,537,631 in the first nine
months of 2004 to $2,055,988 in the same period in 2005, representing a 34%
increase. The details of selling and marketing expenses for the first nine
months of 2005 and 2004 were as follow:

Nine Months Ended September 30,
-------------------------------------------------
2005 2004
----------------------- ---------------------
Payroll expenses for Harbin Bioengineering $ 492,019 $ 343,282
Non payroll expenses for Harbin Bioengineering 917,985 1,193,785
Payroll expenses for HSPL 82,219 - -
Non payroll expenses HSPL 543,027 - -
Overhead for offices in Hong Kong and US 20,738 564

----------------------- ---------------------
TOTAL $ 2,055,988 $ 1,537,631
======================= =====================




In the first nine months of 2005, the Company incurred $492,019 for payroll expenses of our sales and marketing executives and employees in Harbin Bioengineering, or an increase of 43% from $343,282 in the same period in 2004. This increase was mainly due to an increase in the number of employees in our sales and marketing department. In the first nine months of 2005, HSPL incurred $82,219 in payroll expenses for sales and marketing executives and employees. In the same period last year there was no such expense in the Company because the operations of HSPL was not yet consolidated into the Company.

Despite the increase in our sales and marketing executives and employees, compared to the first nine months of 2004, Harbin Bioengineering has reduced its . . .

[teerecs]

hmmm, wenn ich das lese ist doch soweit noch alles ok.

oder wie seht ihr das?

[berndh70]

@wachsam:
Danke, ich bin auch wirklich froh, denn das mit AOB war der beste Deal den ich seit langem gemacht habe.

Ansonsten ist das mal wieder typisch Börse. Umsatz verdoppelt, Gewinn verdoppelt und jeder schmeißt seine Aktien auf den Markt, weil er hofft, das nach diesen Daten alle kaufen - und schwupps, das genaue Gegenteil ist der Fall. Naja, zu viel Angebot eben.

Aber das ändert nichts an den fundamental guten Daten des Unternehmens!

Und eine Aktie, die sich innerhalb eines haben Jahres fast versechsfacht hat, die darf auch mal um 20% fallen. Wartet ein paar Tage, und die ersten werden die Kurse wieder für einen Einstieg nutzen. Das ist jedenfalls meine Meinung...

[teerecs]

eps:
1rd quarter: 0,05
2nd quarter: 0,08
3rd quarter: 0,08

zusammen: 0,21

hoffentlich schaffen sie im vierten 0,09, das wäre ein eps für das gesamtjahr von 0,30 und ein kgv von 20.

gewachsen sind sie ja ordentlich, aber die anzahl der aktien hat sich auch erhöht. somit ist der effekt auf den gewinn pro aktie nicht so groß wie das wachstum.

wenn sie jetzt weiterwachsen und sich an der aktienanzahl nichts ändert, dann dürfte das heute nur eine ordentliche korrektur gewesen sein.

mal paar tage abwarten!

[berndh70]

REVENUES: $ 34,962,489 (2005) | $ 19,283,134 (2004)
COMPREHENSIVE INCOME: $ 10,102,729 (2005) | $ 5,008,833 (2004)
Diluted weighted common shares outstanding: 44,076,235(2005) | 33,594,477 (2004)
Diluted earning per share: $ 0.22 2005) | $ 0.15 (2004)

Also:
Umsatz + 81%
Gewinn nach Steuern + 101%
Anzahl der Aktien + 31%
Gewinn/Aktie + 46%

Und mit dem Cashflow scheint es auch ganz in Ordnung, sprich die werden für Ihre Ware auch bezahlt.

Ich versteh die Aufregung da drübern nicht. Hab ich was übersehen? Bitte verbessert mich, wenn ich falsch liege.

[berndh70]

American Oriental Bioengineering Inc. Announces Record Revenues and Earnings for the Third Quarter of 2005; Revenues Increase 81.9%; Net Income Increases 65.5%

HONG KONG--(BUSINESS WIRE)--Nov. 14, 2005--American Oriental Bioengineering Inc. (AMEX: AOB), an emerging Chinese company that produces and distributes a broad range of pharmaceutical and nutraceutical products, today announced financial results for the third quarter and nine-month period ended Sept. 30, 2005.

Key Financial Indicators
(all numbers for this table in thousands, except share and per-share
amounts)

Q3 2005 Q3 2004 Percentage Change

Consolidated revenues $13,407 $7,373 81.9%
Cost of revenues $4,912 $2,436 101.6%
Gross profit $8,495 $4,936 72.1%
Total operating expenses $3,856 $2,284 68.9%
Income from operations $4,639 $2,652 74.9%
Net Income $3,710 $2,241 65.5%
EPS - Basic $0.08 $0.07 14.3%
EPS - Diluted $0.08 $0.07 14.3%
Diluted shares 44,076,235 33,594,477 31.2%

For the third quarter, the company announced revenues of $13.4 million, an increase of 81.9 percent compared to the $7.4 million reported for the third quarter of 2004. The increase in revenue was attributable to growth in the company`s Plant-Based Pharmaceutical (PBP) and Plant-Based Nutraceutical (PBN) products, including the contribution of the Heilongjiang Songhuajiang Pharmaceutical Co. Ltd ("HSPL") acquisition completed in November 2004 which added the Shanghuangling Lyophilize Powder Injection to the company`s PBP product line. Excluding the $4.3 million contribution from HSPL, organic revenues grew 23.8 percent for the third quarter of 2005 compared to the third quarter of 2004.

For the third quarter, PBP products comprised $8.6 million, or 64.3 percent of total sales, while PBN products comprised $4.8 million, or 35.7 percent of total sales. During the third quarter of 2005, the sales of PBP products increased approximately $5.5 million, or 173.9 percent compared to the same period in 2004, driven by the addition of the Shanghuangling Lyophilize Powder Injection to the company`s PBP product line and growth in the company`s Cease Enuresis Soft Gel sales, one of the few PBP approved by the Chinese government for the treatment of bedwetting and nighttime urination. Shanghuangling Lyophilize Powder Injection accounted for 49.6 percent of PBP revenue and the Cease Enuresis Soft Gel products contributed $3.0 million, representing 35.2 percent of total PBP revenues. Shanghuangling Lyophilize Powder Injection did not contribute to revenues during the third quarter 2004. Cease Enuresis Soft Gel products increased 61.2 percent for the third quarter of 2005 compared to the third quarter of 2004.

PBN sales increased by $558,061 or 13.2 percent compared to last year as the company continued to improve its marketing efforts geared toward educating consumers on the benefits of using soy-based peptide products. The company`s largest product as a percentage of revenue for its PBN segment was the Peptide 1*100, which represented $3.1 million, or 65.5 percent, of revenues for this line.

Cost of goods sold was $4.9 million, an increase of 101.6 percent compared to the $2.4 million reported for the same period a year ago, resulting in gross margins of 63.4 percent for the third quarter of 2005 compared to gross margins of 67.0 percent for the third quarter last year. The company`s gross margins were impacted by higher costs associated with manufacturing the HSPL product, which was not factored into the company`s third quarter 2004 results.

Selling and marketing expenses increased 67.2 percent to $850,167, advertising expenses increased 3.8 percent to $756,541 and general and administrative expenses increased 117.3 percent to $1.9 million, in each case compared to the third quarter of 2004. Collectively, total operating expenses were $3.9 million, an increase of 68.9 percent compared to the $2.3 million reported for the same period last year as the company increased expenses related to the HSPL acquisition and other initiatives to support operational growth. Operating expenses as a percentage of sales were 28.8 percent during the third quarter of 2005 compared to 30.9 percent for the third quarter of 2004.

Operating income increased to $4.6 million, or 74.9 percent, from $2.7 million for the third quarter of 2004. Operating margin was 34.6 percent compared to 36.0 percent during the third quarter of 2004, with the decrease due to the integration of HSPL operations as mentioned previously.

Net income was $3.7 million, as compared to net income of $2.2 million for the third quarter last year, an increase of 65.5 percent. Basic and diluted earnings per share for the third quarter of 2005 were $0.08 per share, as compared to $0.07 per share for the third quarter of 2004. The company utilized 44.1 million weighted diluted shares in this calculation, representing a 31.2 percent increase from the 33.6 million weighted diluted shares for the third quarter of 2004.

"This was an exciting quarter for American Oriental Bioengineering as we achieved a listing on the American Stock Exchange, made significant improvements in our balance sheet, continued to integrate the acquired assets of HSPL while continuing our strong financial performance," commented Tony Liu, chairman and CEO of American Oriental Bioengineering. "During the third quarter, we continued to deliver solid revenue and earnings growth while further positioning AOBO to gain market share by expanding our geographic footprint and distribution channels. We made a strategic decision to expand the marketing of our PBN products and subsequently opened our first retail location in Hong Kong called `Life Peptide.` This location will act as a showpiece to promote and educate consumers on the benefits of soy-based peptide products as a means to address improved overall health and well-being. Additionally, our soy-based peptide products will be offered in over 100 independent retail locations in the region. As we continue to penetrate the large and growing Chinese market with our superior products coupled with favorable macro demographic and product trends, we believe AOBO is well positioned for ongoing growth and profitability."

For the nine-month period ended Sept. 30, 2005, the company announced revenues of $35.0 million, an increase of 81.3 percent compared to the $19.3 million reported for the first nine months of 2004. The company`s PBP products contributed $22.1 million in revenues, up 112 percent compared to the first nine months of 2004. For the nine months ended Sept. 30, 2005, $10.9 million of the revenue growth was contributed by SLPI, or 49.6 percent of total PBP revenues, and Cease-Enuresis Soft Gel products contributed $7.3 million, or 33.2 percent, of total PBP revenue, representing a 53.4 percent growth compared to the same nine-month period in 2004.

For the nine-month period ended Sept. 30, 2005, cost of goods sold was $12.7 million, an increase of 108.7 percent compared to the $6.1 million from the same period a year ago, resulting in gross margin of 63.6 percent for the first nine months of 2005 compared to gross margin of 68.4 percent for the same period last year, with gross margin decreasing due to the inclusion of HSPL products. Total operating expenses were $10.1 million, an increase of 42.5 percent compared to the $7.1 million reported for the same period last year. Operating expenses as a percentage of sales were 28.9 percent compared to 36.8 percent for the same period in 2004. Operating income was $12.1 million, an increase of 99.1 percent compared to $6.1 million reported in the same period. Operating margins were 34.7 percent, compared to 31.6 percent for the same period last year, as the company benefited from a faster rate of growth in sales compared to expenses. Net income was $9.2 million compared to net income of $5.0 million during the comparable period for 2004, an increase of 84.6 percent. Basic and diluted earnings per share were $0.22 per share compared to $0.15 per share for the nine-month period last year. The company utilized 41.3 million weighted diluted shares in the calculation compared to 33.1 million weighted diluted shares in the same period last year.

Balance Sheet

The company completed the quarter with $19.1 million in cash and cash equivalents, inclusive of the $11.0 million received from its class "A" and "B" warrants exercises by the end of September 2005. This compares to $11.4 million in cash as of Dec. 31, 2004. The company reported $3.7 million in bank loans as of Sept. 30, 2005, as compared to $5.1 million as of Dec. 31, 2004. During the first nine months of 2005 the company generated $3.9 million in positive cash flows from operations.

"Today, with over 100 products in our portfolio and over 10,000 points of sale, we believe we are a far stronger and more diverse company than just one year ago," Liu continued. "With a stronger cash position and a more defined and effective distribution channel, we are able to target multiple growth strategies in addition to having the resources available to capitalize on complementary acquisition opportunities within the Chinese marketplace. We are initiating plans to penetrate new markets and drive organic growth in terms of both revenue and earnings, while positioning ourselves as a recognizable entity in China for plant-based herbal remedies.

Teleconference Information

The company`s management will host a third quarter earnings conference call today at 4:30 p.m. Eastern time today. Interested participants should call 888-896-0863 when calling within the United States or 973-582-2741 when calling internationally. There will be a playback available until Nov. 21, 2005. To listen to the playback, please call 877-519-4471 when calling within the United States or 973-341-3080 when calling internationally. Please use passcode 6684462 for the replay.

This call is being webcast by ViaVid Broadcasting and can be accessed at American Oriental Bioengineering`s Web site at http://www.bioaobo.com. The webcast may also be accessed at ViaVid`s Web site at http://www.viavid.net. The webcast can be accessed until Dec. 14, 2005, on either site.

About American Oriental Bioengineering Inc.

American Oriental Bioengineering Inc. (AOB) uses proprietary processes for producing soybean protein peptide more efficiently than traditional extracting techniques. These techniques are used to manufacture and formulate supplemental and medicinal products. Soybean peptides are used widely in general food, health food products and medicines, among other applications. AOB also produces Cease-Enuresis Soft Gel, one of the few Chinese FDA-approved first grade, prescription medicines that is specially formulated to help alleviate bed-wetting and incontinence. The company is a leading producer of products in both the pharmaceuticals and nutraceuticals areas in China. For more information, visit http://www.bioaobo.com.

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in statements filed from time to time with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

American Oriental Bioegineering Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
ASSETS
------
SEPT. 30, DEC. 31,
2005 2004
----------- -----------
(UNAUDITED)
CURRENT ASSETS
Cash and cash equivalents $19,074,261 $11,404,149
Accounts receivable, net of allowance for
doubtful accounts of $307,106 and $0,
respectively 7,691,130 4,736,901
Inventories, net of provision of $606,927
and $0, respectively 10,506,880 5,673,059
Advances to suppliers 520,884 518,589
Other receivables 14,210 156,062
Prepaid expenses 138,400 -
Due from employees 410,808 182,099
Deferred consulting expenses 962,328 1,686,652
----------- -----------
Total Current Assets 39,318,901 24,357,511

PLANT AND EQUIPMENT, NET 7,766,247 8,068,776
DEFERRED TAX ASSETS 581,227 159,958
LICENSE, NET 486,592 542,168
CONSTRUCTION IN PROGRESS 6,481,073 1,836,714
LAND USE RIGHTS, NET 7,950,592 7,871,497
----------- -----------
TOTAL ASSETS $62,584,632 $42,836,624
------------ =========== ===========

LIABILITIES AND SHAREHOLDERS` EQUITY
------------------------------------
CURRENT LIABILITIES
Accounts payable $ 1,407,773 755,266
Short-term bank loans 3,707,365 5,060,241
Common stock to be issued 2,780,328 -
Taxes payable 1,231,258 1,096,545
Other payables and accrued expenses 1,434,031 1,064,411
Due to officers - 1,404,522
Customer deposits 302,054 160,504
Current portion of obligations under capital
leases 13,577 12,952
----------- -----------
Total current liabilities 10,876,386 9,554,441

LONG-TERM PORTION OF OBLIGATIONS UNDER CAPITAL
LEASES 23,528 34,548
DEFERRED TAX LIABILITIES 210,885 107,201
----------- -----------
TOTAL LIABILITIES 11,110,799 9,696,190
----------- -----------

SHAREHOLDERS` EQUITY
Preferred stock, $0.001 par value; 2,000,000
shares authorized; 1,000,000 shares issued
and outstanding at Sept. 30, 2005, and
Dec. 31, 2004, respectively 1,000 1,000
Common stock, $0.001 par value; 60,000,000
shares authorized; 48,264,739 and 39,746,827
shares issued and outstanding, respectively 48,265 39,747
Additional paid-in capital 25,122,455 16,900,303
Accumulated other comprehensive income 854,058 -
Retained earnings (the restricted portion of
retained earnings is $1,294,689 and
$1,294,689 at Sept. 30, 2005, and Dec. 31,
2004, respectively) 25,448,055 16,199,384
----------- -----------
Total Shareholders` Equity 51,473,833 33,140,434
----------- -----------
TOTAL LIABILITIES AND SHAREHOLDERS` EQUITY $62,584,632 $42,836,624
------------------------------------------ =========== ===========


AMERICAN ORIENTAL BIOENGINEERING INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(UNAUDITED)

Three Months Ended Nine Months Ended
Sept. 30, Sept. 30,
2005 2004 2005 2004
----------- ----------- ------------ -----------

REVENUES $13,407,237 $ 7,372,555 $ 34,962,489 $19,283,134
COST OF GOODS SOLD (4,911,990) (2,436,157) (12,728,309) (6,098,743)
----------- ----------- ------------ -----------
GROSS PROFIT 8,495,247 4,936,398 22,234,180 13,184,391

Selling and marketing (850,167) (508,477) (2,055,988) (1,537,631)
Advertising (756,541) (728,802) (2,160,625) (2,336,006)
General and
administrative (1,939,514) (892,701) (4,968,708) (2,757,745)
Merger cost - (8,333) - (24,999)
Depreciation and
amortization (310,267) (145,619) (919,195) (436,674)
----------- ----------- ------------ -----------
INCOME FROM
OPERATIONS 4,638,758 2,652,466 12,129,664 6,091,336

INTEREST INCOME
(EXPENSE), NET 197,150 (23,694) 40,074 (71,485)

OTHER INCOME, NET 577 56,634 (6,700) 83,376

----------- ----------- ------------ -----------
INCOME BEFORE INCOME
TAXES 4,836,485 2,685,406 12,163,038 6,103,227
Income Taxes (1,126,721) (444,361) (2,914,367) (1,094,394)
----------- ----------- ------------ -----------

NET INCOME 3,709,764 2,241,045 9,248,671 5,008,833

Foreign currency
translation gain 854,058 - 854,058 -

----------- ----------- ------------ -----------
COMPREHENSIVE INCOME $ 4,563,822 $ 2,241,045 $ 10,102,729 $ 5,008,833
-------------------- =========== =========== ============ ===========

NET INCOME PER SHARE
BASIC $ 0.08 $ 0.07 $ 0.22 $ 0.15
DILUTED $ 0.08 $ 0.07 $ 0.22 $ 0.15

WEIGHTED AVERAGE
NUMBER OF SHARES
OUTSTANDING
BASIC 44,000,009 33,570,957 41,239,172 33,073,499
DILUTED 44,076,235 33,594,477 41,267,329 33,097,224

CONTACT: American Oriental Bioengineering Inc.Lily Li, 212-786-7568 (U.S.) or [phone] (China)
[e-mail]
or
Hayden Communications
Matt Hayden, 858-704-5065 (Investors)
[e-mail]

SOURCE: American Oriental Bioengineering Inc.

[berndh70]

Aktie gestern um 15% gefallen. Diese News können´s aber doch eigentlich nicht gewesen sein, oder?

HONG KONG--(BUSINESS WIRE)--Nov. 23, 2005--American Oriental Bioengineering Inc. (AMEX: AOB), a leading Chinese manufacturer and distributor of pharmaceutical and nutraceutical products, announced today that it is conducting a private offering to accredited investors with respect to an offering of up to 12,500,000 units, each unit consisting of one share of its common stock and three-tenths of a warrant to purchase one share of its common stock, at a price of $4.80 per unit, for anticipated aggregate proceeds of up to approximately $60 million. The proceeds, net of offering fees and expenses, will be used to finance acquisitions and for general corporate purposes.

The shares and warrants have not been registered under the Securities Act of 1933, as amended, (the "Securities Act"), or any state securities laws, and unless so registered, the securities may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws. American Oriental Bioengineering is obligated to register the shares, including the shares issuable upon exercise of the warrants, for resale on a registration statement to be filed within 45 days of the closing of the transaction and to be effective within 90 days of the closing of the transaction.

After accounting for conversion of the warrants issued pursuant to the transaction, American Oriental Bioengineering will be issuing 17,387,500 shares of its common stock. The company currently has approximately 9,700,000 shares of common stock available for issuance. As a result, the company is required to obtain shareholder approval to amend its certificate of incorporation to increase the number of authorized shares that it is permitted to issue. In addition, the rules of the American Stock Exchange require the company to obtain shareholder approval as a result of the issuance of greater than 20% of its currently outstanding stock at a discount to the current market price. A portion of the proceeds of the offering will be held in escrow until the company obtains the required shareholder approval.

This announcement shall not constitute an offer to sell or a solicitation of an offer to buy any of these securities. This press release is being issued pursuant to and in accordance with Rule 135c under the Securities Act.

[berndh70]

Der Kursverlauf bereitet zwar gerade keine Freude, aber hier mal wieder ein paar News. Und ich denke, wenn jemand 1,2 Mio. USD in die Firma investiert, dann hat er sich sicher was dabei gedacht - wie wir auch...

-------------------------------------

LONDON (AFX) - SovGEM Ltd, the emerging market finance house, said it has invested 1.2 mln usd in American Oriental Bioengineering Inc.

AIM-listed SovGEM said it bought 250,000 shares through a private placement organised by Westminster Securities Corporation, a NYSE member firm. The registration of these shares is subject to the registration requirements of the US Securities Act of 1933 and also in part upon the approval of AOB shareholders.

AOB is a Chinese producer and distributor of a broad range of pharmaceutical and nutraceutical products for the Chinese domestic market.

[e-mail]

nes/

COPYRIGHT

Copyright AFX News Limited 2005. All rights reserved.

The copying, republication or redistribution of AFX News content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News.

AFX News and the AFX Financial News logo are registered trademarks of AFX News Limited

[berndh70]

P.S.: Die haben also 4.80 USD pro Aktie gezahlt!